Solid Dosage Form Market Industry Developments and Expansion Plans

Solid Dosage Form Market Overview

Oral solid dosage forms (OSDFs) — including tablets, capsules, granules, powders, and related oral delivery systems — remain the foundation of pharmaceutical administration due to their stability, ease of use, patient compliance, and cost efficiency. Globally, the oral solid dosage pharmaceutical market is valued at over USD 700 billion in 2024 and is expected to surpass USD 1.1 trillion by 2030, growing at a compound annual growth rate (CAGR) of about 6–7%.

The contract development and manufacturing (CDMO/CMO) segment for oral solids alone is valued at over USD 36 billion, projected to grow at nearly 6% CAGR by 2030. The continued outsourcing of manufacturing, growing chronic disease prevalence, and increasing demand for modified-release formulations are major growth catalysts.

The overall market scale varies depending on scope — whether referring to finished formulations, upstream excipients, or outsourcing services — but all forecasts indicate a robust multi-hundred-billion-dollar market with consistent mid-single-digit annual growth through 2030 and beyond.

Key Growth Drivers and Trends

Patent expirations and generic proliferation – Expiry of blockbuster drugs drives the rise of generics, increasing overall production volumes of solid dosage forms.
Ease of manufacture and stability – Solid dosage forms are preferred over injectables due to simpler handling, better stability, and reduced cold chain needs.
Chronic disease and aging populations – Noncommunicable diseases such as diabetes, hypertension, and cardiovascular disorders increase the need for daily oral medications.
Technological advancement – Controlled-release, continuous manufacturing, and digital formulation platforms improve product performance and efficiency.
Outsourcing trend – More pharmaceutical companies are outsourcing development and production to specialized CDMOs to save time and investment.
Personalized and patient-centric dosing – Growth in pediatric, geriatric, and customized dose formulations drives innovation in orally disintegrating tablets and mini-tablets.
Regulatory and quality focus – Tighter impurity limits and the emphasis on Quality by Design (QbD) frameworks drive modernization across production lines.

The solid dosage market’s growth is thus driven by both volume (generics, chronic diseases) and value (innovation, advanced formulation technologies).

Solid Dosage Form Market Segmentation

Below are four main segments and their subsegments that define the global solid dosage market structure.

1. By Dosage Form / Format

Subsegments: Tablets, Capsules, Powders and Granules, and Other Emerging Forms.

Tablets: The most common and versatile dosage form, including immediate-release, sustained-release, and orally disintegrating tablets. Tablets dominate the market because of their cost efficiency, dosage precision, and ease of production. They are used across nearly all therapeutic areas.

Capsules: Used when APIs are sensitive to compression or need multiparticulate delivery. Hard and soft gelatin capsules are popular in both generic and nutraceutical sectors. Capsules also allow enteric coatings for delayed or targeted release.

Powders and Granules: These include bulk powders for reconstitution or sachet packaging, often used for antibiotics or pediatric formulations. They are also intermediate forms used in tablet and capsule manufacturing.

Other Forms: These include orally disintegrating films (ODFs), mini-tablets, and oral strips — formats designed for patients with swallowing difficulties or needing fast disintegration. These are emerging strongly in pediatric and geriatric therapy areas.

Significance: Tablets maintain dominance in both revenue and volume. However, innovations in capsules and disintegrating forms are capturing new patient populations, enhancing compliance and convenience.

2. By Release or Delivery Mechanism

Subsegments: Immediate Release (IR), Modified or Sustained Release (MR/SR), Targeted or Site-Specific, and Pulsatile or Chronotherapeutic Systems.

Immediate Release (IR): Traditional formulations designed to release the drug quickly after ingestion. They dominate generic and acute-care medicines.

Modified or Sustained Release (MR/SR): Designed to extend the release of active ingredients over a set period to maintain steady blood levels and improve patient adherence. Examples include matrix tablets and coated pellet systems.

Targeted or Site-Specific Release: Uses coatings or polymer matrices to release drugs at specific points in the gastrointestinal tract, such as the stomach or colon. Ideal for drugs that degrade in certain pH environments.

Pulsatile or Chronotherapeutic Systems: Timed-release systems that align with biological rhythms, releasing drugs at specific times, such as morning dosing for hypertension or asthma.

Significance: Immediate-release formulations still dominate by volume, but the market for modified and targeted-release systems is expanding rapidly, offering higher value and differentiation opportunities.

3. By Therapeutic Area

Subsegments: Cardiovascular and Metabolic Diseases, Central Nervous System (CNS) Disorders, Oncology, and Other Therapeutic Categories.

Cardiovascular and Metabolic Diseases: The largest category in terms of volume, encompassing antihypertensives, statins, and antidiabetics. Rising chronic disease prevalence ensures sustained demand.

Central Nervous System Disorders: Includes drugs for depression, anxiety, epilepsy, and Parkinson’s disease. Sustained or delayed-release tablets are common to improve compliance and minimize side effects.

Oncology: The fastest-growing segment. Oral oncology drugs such as kinase inhibitors are replacing hospital infusions, requiring precise, high-potency solid formulations.

Other Categories: Include gastrointestinal, anti-infective, analgesic, and respiratory drugs. Although mature, they continue to generate steady revenues and serve as entry points for generics.

Significance: Oncology solid dosage forms show strong double-digit growth, while cardiovascular and CNS categories ensure baseline stability across the global market.

4. By Manufacturing and Business Model

Subsegments: Integrated Pharmaceutical Companies, Generic Manufacturers, Contract Development and Manufacturing Organizations (CDMOs), and Specialty Innovators.

Integrated Pharmaceutical Companies: Large drug companies such as Pfizer and Novartis manage in-house formulation and manufacturing. They invest heavily in R&D and global quality systems.

Generic Manufacturers: Companies like Teva, Sun Pharma, and Mylan lead this segment, focusing on cost-efficient mass production and rapid launches of off-patent drugs.

CDMOs: Provide end-to-end services including formulation, process development, analytical testing, and large-scale manufacturing. Firms like Catalent, Thermo Fisher, and Lonza dominate this segment.

Specialty and Niche Innovators: Smaller firms specializing in pediatric formulations, 3D printing, or high-potency drugs. They often partner with larger firms or CDMOs for commercialization.

Significance: The outsourcing model is growing as pharma companies move toward asset-light strategies, allowing CDMOs and specialty firms to capture greater market share.

Emerging Technologies, Product Innovations, and Collaborations

The solid dosage industry is undergoing a technology-driven transformation.

3D Printing and Additive Manufacturing

3D printing allows the creation of tablets with complex geometries and layered APIs, enabling personalized dosing and multi-drug combinations in a single pill. The ability to control porosity and dissolution rates makes it a revolutionary tool for precision medicine.

Digital Formulation and Lab Automation

The emergence of “digital formulators” and self-driving labs integrates automation, machine learning, and predictive modeling to optimize formulations. These systems drastically cut development times, reducing experiments and material costs while improving reproducibility.

Advanced Excipients and Smart Polymers

Modern excipients improve solubility, dissolution, and stability for poorly soluble APIs. Co-processed excipients and functional coatings have become key differentiators, enabling controlled-release and taste-masking capabilities.

Continuous Manufacturing

Continuous manufacturing replaces traditional batch processes, providing real-time quality control, reduced waste, and faster scale-up. Regulatory bodies are increasingly encouraging this model under Quality by Design and Process Analytical Technology frameworks.

Collaborative Ventures and Industry Partnerships

Pharma companies, CDMOs, equipment suppliers, and material manufacturers are collaborating more than ever. Partnerships are formed to validate new excipients, develop continuous manufacturing systems, or establish digital twin models for process simulation.

Artificial Intelligence and Machine Learning

AI-driven prediction models are being trained to estimate tablet properties like dissolution time and hardness based on formulation parameters. These predictive models help reduce trial-and-error in formulation design.

High-Potent Formulation Technology

With more low-dose, high-potency drugs entering pipelines, manufacturers are investing in containment technologies, isolators, and microencapsulation systems. The high-potent solid dosage segment is growing faster than the overall market, driven by oncology and hormonal drugs.

Collectively, these innovations enhance quality, accelerate development, and reduce cost, paving the way for personalized, efficient, and flexible solid dosage manufacturing.

Key Players in the Solid Dosage Form Market

The market features a mix of integrated pharmaceutical giants, CDMOs, excipient suppliers, and niche innovators.

1. Catalent, Inc.
A global leader in formulation and manufacturing, Catalent offers advanced controlled-release technologies and continuous manufacturing solutions for oral solids.

2. Thermo Fisher Scientific (Patheon)
Provides development and large-scale manufacturing of tablets and capsules through its Patheon division, focusing on digital integration and modular production.

3. Lonza (Capsugel)
Combines capsule expertise with formulation technologies, offering high-potency handling, enteric coatings, and customized capsule solutions.

4. Pfizer, Novartis, Johnson & Johnson
Major pharma firms with large internal OSD manufacturing capacity and R&D pipelines. They invest heavily in new excipient systems and advanced coatings.

5. Teva, Mylan, Sun Pharma
Key players in the global generics market, focusing on cost-optimized, high-volume production of solid dosage forms across multiple therapeutic areas.

6. Recipharm, Aenova, Siegfried
Mid-sized CDMOs offering flexible production for emerging pharma and biotechnology clients, particularly in Europe and Asia.

7. BASF, DuPont, Evonik, Ashland, Colorcon
Leading excipient suppliers producing coatings, binders, and co-processed excipients vital to modern tablet and capsule production.

8. Technology Innovators
Smaller startups focusing on digital formulation platforms, 3D printing technologies, and smart excipients are gaining strategic collaborations with large pharma and CDMOs.

These companies collectively define the technological and competitive landscape, with partnerships, M&A, and innovation at the core of their growth strategies.

Market Challenges and Potential Solutions

1. Supply Chain Volatility

Challenge: Dependence on global excipient suppliers exposes manufacturers to disruption and cost fluctuations.
Solution: Strengthen regional sourcing, dual suppliers, and predictive logistics systems.

2. Pricing Pressure

Challenge: Fierce generic competition erodes margins.
Solution: Focus on complex generics, high-potent formulations, and differentiated products to sustain value.

3. Regulatory Complexity

Challenge: Increasingly stringent impurity limits and differing regional regulations.
Solution: Invest in Quality by Design, continuous monitoring, and harmonized compliance systems.

4. Scale-Up and Tech Transfer

Challenge: Difficulties in moving from lab to commercial scale without altering critical properties.
Solution: Use process simulation, digital twins, and continuous manufacturing lines to ensure scalability.

5. Technology Integration Costs

Challenge: Implementing advanced tech like automation and 3D printing requires capital and training.
Solution: Adopt phased implementation, form partnerships, and seek technology grants to reduce upfront burden.

6. Intellectual Property and Standards

Challenge: Proprietary technologies can limit interoperability across the industry.
Solution: Promote open standards and consortia for data sharing and regulatory collaboration.

7. Safety in High-Potent Manufacturing

Challenge: Increased potency of APIs raises containment and cross-contamination risks.
Solution: Use dedicated high-potent facilities, isolators, and validated containment systems.

Future Outlook and Growth Trajectory

The future of the solid dosage form market is characterized by steady growth, digital transformation, and innovation-led differentiation.

Global Market Growth: Expected CAGR between 4.5% and 6.5% through 2030, reaching or surpassing USD 1 trillion in market value.
Advanced Formulations: Controlled-release, targeted, and chronotherapeutic systems will outpace traditional formats in value share.
Outsourcing Acceleration: CDMOs and CMOs will capture a growing portion of the market as pharma companies streamline operations.
Technology Integration: Continuous manufacturing, AI-driven formulation, and digital labs will become standard across large organizations.
Personalization: Demand for 3D-printed and patient-specific dosages will increase, particularly in high-income markets.
Regional Shift: Asia-Pacific will remain the fastest-growing region due to cost advantages, manufacturing capacity, and expanding healthcare access.
Sustainability: Eco-friendly excipients, waste reduction, and energy-efficient facilities will become key competitive factors.

Overall, the market will move from being dominated by volume-based generics to innovation-led, technology-driven manufacturing ecosystems. Companies that combine digital intelligence, formulation science, and flexible manufacturing will emerge as leaders.

Frequently Asked Questions (FAQs)

1. What is a solid dosage form?
A solid dosage form is a drug formulation intended for oral administration in solid state, including tablets, capsules, powders, granules, and oral films.

2. Why are solid dosage forms dominant in pharmaceuticals?
They are cost-effective, stable, easy to handle, and suitable for mass production and patient compliance, making them preferred over injectables and liquids.

3. Why do pharmaceutical companies outsource solid dosage production?
Outsourcing helps reduce capital investment, accelerates development, and provides access to specialized manufacturing technologies and regulatory expertise.

4. How are emerging technologies changing the market?
Technologies like 3D printing, AI-based formulation, and continuous manufacturing are enabling personalized medicine, faster scale-up, and better quality control.

5. What challenges could slow down market growth?
Key challenges include regulatory hurdles, pricing pressure, supply chain issues, and the high cost of integrating advanced technologies. Addressing these through collaboration, regionalization, and digitalization will sustain growth.

Search This Blog

Informed Strategy